mexiletine has been researched along with Batten Turner Congenital Myopathy in 19 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Excerpt | Relevance | Reference |
---|---|---|
"we report on the first case of a woman affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and recessive myotonia congenita (MC), treated with mexiletine." | 7.96 | Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option. ( Biasini, F; Bramanti, P; Calabrò, RS; Naro, A; Portaro, S, 2020) |
"Mexiletine treatment started at 200 mg/day and was up-titrated by 200 mg increment each three days to reach a maximum dose of 600 mg/day for total treatment duration of 18 days for each cross-over period." | 7.01 | Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. ( Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021) |
"we report on the first case of a woman affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and recessive myotonia congenita (MC), treated with mexiletine." | 3.96 | Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option. ( Biasini, F; Bramanti, P; Calabrò, RS; Naro, A; Portaro, S, 2020) |
"Mexiletine treatment started at 200 mg/day and was up-titrated by 200 mg increment each three days to reach a maximum dose of 600 mg/day for total treatment duration of 18 days for each cross-over period." | 3.01 | Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. ( Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021) |
"We evaluated 21 patients with recessive myotonia congenita referred to our institute from 1990 to 2013 and treated with mexiletine chlorhydrate." | 1.42 | Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita. ( D'Amico, A; Desaphy, JF; Lo Monaco, M; Luigetti, M; Modoni, A, 2015) |
"A 27-year-old woman presented with paramyotonia congenita since her childhood." | 1.40 | Focal and abnormally persistent paralysis associated with congenital paramyotonia. ( David, A; Magot, A; Péréon, Y; Sternberg, D, 2014) |
"Recessive myotonia congenita (Becker's disease)." | 1.33 | Myotonia congenita--a cause of muscle weakness and stiffness. ( Bouchard, JP; Chrestian, N; Dupré, N; Puymirat, J, 2006) |
"He had myotonia congenita." | 1.30 | Unusual causes of stiffness in two hockey players. ( Burnham, R, 1997) |
"Treatment with mexiletine led to resolution of the abnormalities exhibited during a short exercise test and repetitive stimulation following ice bath immersion." | 1.29 | Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. ( Barohn, RJ; Jackson, CE; Ptacek, LJ, 1994) |
"A sporadic event of myotonia congenita in a infant admitted to the Paediatric Clinic for frequent crises of apnoea, cyanosis, vomiting and difficult feeding is reported." | 1.28 | Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. ( Calevro, L; Ceccarelli, M; Rossi, B; Siciliano, G; Tarantino, E, 1992) |
"A case of generalized myotonia with autosomal recessive transmission related to Becker's type is reported." | 1.27 | [Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]. ( Pouget, J; Serratrice, G, 1983) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (21.05) | 18.7374 |
1990's | 4 (21.05) | 18.2507 |
2000's | 2 (10.53) | 29.6817 |
2010's | 6 (31.58) | 24.3611 |
2020's | 3 (15.79) | 2.80 |
Authors | Studies |
---|---|
Vicart, S | 2 |
Franques, J | 1 |
Bouhour, F | 1 |
Magot, A | 2 |
Péréon, Y | 2 |
Sacconi, S | 1 |
Nadaj-Pakleza, A | 1 |
Behin, A | 1 |
Zahr, N | 1 |
Hézode, M | 1 |
Fournier, E | 1 |
Payan, C | 1 |
Lacomblez, L | 1 |
Fontaine, B | 2 |
Stunnenberg, BC | 1 |
LoRusso, S | 1 |
Arnold, WD | 1 |
Barohn, RJ | 2 |
Cannon, SC | 1 |
Griggs, RC | 1 |
Hanna, MG | 1 |
Matthews, E | 1 |
Meola, G | 1 |
Sansone, VA | 1 |
Trivedi, JR | 1 |
van Engelen, BGM | 1 |
Statland, JM | 1 |
Portaro, S | 2 |
Biasini, F | 1 |
Bramanti, P | 2 |
Naro, A | 2 |
Calabrò, RS | 2 |
Bramanti, A | 1 |
Leo, A | 1 |
Manuli, A | 1 |
Balletta, T | 1 |
Trinchera, A | 1 |
Desaphy, JF | 3 |
Carbonara, R | 2 |
Costanza, T | 1 |
Conte Camerino, D | 2 |
David, A | 1 |
Sternberg, D | 1 |
Lo Monaco, M | 2 |
D'Amico, A | 2 |
Luigetti, M | 1 |
Modoni, A | 2 |
Roussel, J | 1 |
Imbrici, P | 1 |
Pagliarani, S | 1 |
Lucchiari, S | 2 |
Ginanneschi, F | 1 |
Mignarri, A | 1 |
Ulzi, G | 1 |
Comi, GP | 1 |
Rossi, A | 1 |
Dotti, MT | 1 |
Brooke, MH | 1 |
Chrestian, N | 1 |
Puymirat, J | 1 |
Bouchard, JP | 1 |
Dupré, N | 1 |
Pouget, J | 1 |
Serratrice, G | 1 |
Jackson, CE | 1 |
Ptacek, LJ | 1 |
Burnham, R | 1 |
Kwieciński, H | 1 |
Ryniewicz, B | 1 |
Ostrzycki, A | 1 |
Ceccarelli, M | 1 |
Rossi, B | 2 |
Siciliano, G | 2 |
Calevro, L | 1 |
Tarantino, E | 1 |
Leheup, B | 1 |
Himon, F | 1 |
Morali, A | 1 |
Brichet, F | 1 |
Vidailhet, M | 1 |
Nezu, A | 1 |
Yamashita, S | 1 |
Miyake, S | 1 |
Hayashi, M | 1 |
Iwamoto, H | 1 |
Sartucci, F | 1 |
1 review available for mexiletine and Batten Turner Congenital Myopathy
Article | Year |
---|---|
Guidelines on clinical presentation and management of nondystrophic myotonias.
Topics: Acetazolamide; Age of Onset; Carbonic Anhydrase Inhibitors; Chloride Channels; Electrodiagnosis; Ele | 2020 |
2 trials available for mexiletine and Batten Turner Congenital Myopathy
Article | Year |
---|---|
Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mexiletine; Middle Aged; | 2021 |
Treatment of myotonia with antiarrhythmic drugs.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Drug Admi | 1992 |
16 other studies available for mexiletine and Batten Turner Congenital Myopathy
Article | Year |
---|---|
Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option.
Topics: Adult; Chronic Disease; Female; Follow-Up Studies; Humans; Mexiletine; Myotonia Congenita; Polyradic | 2020 |
Beyond the muscular involvement in non-dystrophic myotonias: The emerging role of neuromodulation.
Topics: Adult; Analysis of Variance; Anti-Arrhythmia Agents; Electromyography; Evoked Potentials, Motor; Fem | 2018 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle | 2014 |
Focal and abnormally persistent paralysis associated with congenital paramyotonia.
Topics: Female; Humans; Mexiletine; Mutation; Myotonia Congenita; NAV1.4 Voltage-Gated Sodium Channel; Paral | 2014 |
Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.
Topics: Action Potentials; Adolescent; Adult; Aged; Child; Evoked Potentials, Motor; Female; Humans; Male; M | 2015 |
Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation.
Topics: Cell Line; Child; Diagnosis, Differential; Female; Flecainide; Humans; Mexiletine; Mutation; Myotoni | 2016 |
Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita.
Topics: Action Potentials; Adult; Electromyography; Female; Humans; Male; Mexiletine; Muscle Contraction; Mu | 2017 |
Fiction: the Christmas card.
Topics: Activities of Daily Living; Adult; Aging; Anecdotes as Topic; Anti-Arrhythmia Agents; Humans; Male; | 2005 |
Myotonia congenita--a cause of muscle weakness and stiffness.
Topics: Diagnosis, Differential; Electromyography; Female; Genes, Recessive; Humans; Mexiletine; Middle Aged | 2006 |
[Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine].
Topics: Adult; Exercise Therapy; Female; Humans; Mexiletine; Muscle Hypotonia; Myotonia Congenita; Propylami | 1983 |
Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy.
Topics: Cold Temperature; Electric Stimulation; Electromyography; Exercise Test; Female; Humans; Mexiletine; | 1994 |
Unusual causes of stiffness in two hockey players.
Topics: Adolescent; Adult; Hockey; Humans; Male; Mexiletine; Myotonia; Myotonia Congenita | 1997 |
Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine.
Topics: Electromyography; Humans; Infant, Newborn; Male; Mexiletine; Myotonia Congenita | 1992 |
[Value of mexiletine in the treatment of Thomsen-Becker myotonia].
Topics: Drug Resistance; Humans; Infant, Newborn; Male; Mexiletine; Myotonia Congenita; Propylamines; Time F | 1986 |
[Effective treatment of paramyotonia congenita by mexiletene].
Topics: Adolescent; Humans; Male; Mexiletine; Myotonia Congenita; Propylamines | 1986 |
[Therapy of myotonia congenita].
Topics: Adult; Female; Humans; Male; Mexiletine; Myotonia Congenita | 1986 |